** Shares of drug developer Disc Medicine rise ~28.6% to $60.60, highest since March
** Co says the FDA gave positive feedback supporting the design of a trial that will evaluate its genetic disorder drug bitopertin
** Bitopertin is being developed for the treatment of Erythropoietic protoporphyria $(EPP.UK)$, a rare inherited metabolic disorder
** IRON says the drug has potential for FDA's accelerated approval based on existing data
** "Improved approval timelines and clarification of confirmatory trial design are significant positives to IRON shares," says BMO Capital Markets
** Stock up 15.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。